Multiple Sclerosis Research Today is a free monthly online journal that collates and summarizes the latest research about Multiple Sclerosis, including details on diagnosis, symptoms, treatment, prognosis.

Volume 2 (2005), Issue 6 (June)

1. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab.
   Nat Rev Drug Discov, 4(6): 510-8. [Abstract] [Full-text]
2. Cannabinoid influence on cytokine profile in multiple sclerosis.
   Clin Exp Immunol, 140(3): 580-5. [Abstract] [Full-text]
3. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis.
   Acta Neurol Scand, 112(1): 1-5. [Abstract] [Full-text]
4. Sparse multifocal stimuli for the detection of multiple sclerosis.
   Ann Neurol, 57(6): 904-13. [Abstract] [Full-text]
5. RON-regulated innate immunity is protective in an animal model of multiple sclerosis.
   Ann Neurol, 57(6): 883-95. [Abstract] [Full-text]
6. (alpha)B-crystallin in cerebrospinal fluid of patients with multiple sclerosis.
   Clin Chim Acta, 356(1): 95-101. [Abstract] [Full-text]
7. Spinal and cranial hypertrophic neuropathy in multiple sclerosis.
   Muscle Nerve, 31(6): 772-9. [Abstract] [Full-text]
8. Interaction between eye and hand movements in multiple sclerosis patients with intention tremor.
   Mov Disord, 20(6): 705-13. [Abstract] [Full-text]
9. An examination of four models predicting fatigue in multiple sclerosis.
   Arch Clin Neuropsychol, 20(5): 631-46. [Abstract] [Full-text]
10. Abnormal heart rate and blood pressure responses to baroreflex stimulation in multiple sclerosis patients.
    Clin Auton Res, 15(3): 213-8. [Abstract] [Full-text]
11. Disability and mortality in a cohort of multiple sclerosis patients: a reappraisal.
    Neuroepidemiology, 25(1): 15-8. [Abstract] [Full-text]
12. Magnetic resonance spectroscopy as a measure of brain damage in multiple sclerosis.
    J Neurol Sci, 233(1): 203-8. [Abstract] [Full-text]
13. Reduction of brain volume in MS. MRI and pathology findings.
    J Neurol Sci, 233(1): 199-202. [Abstract] [Full-text]
14. Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate.
    J Neurol Sci, 233(1): 173-7. [Abstract] [Full-text]
15. Glutamate inhibition in MS: the neuroprotective properties of riluzole.
    J Neurol Sci, 233(1): 113-5. [Abstract] [Full-text]
16. Mechanisms of CNS remyelination--the key to therapeutic advances.
    J Neurol Sci, 233(1): 87-91. [Abstract] [Full-text]
17. Stem cell and progenitor cell transplantation in multiple sclerosis: the discrepancy between neurobiological attraction and clinical feasibility.
    J Neurol Sci, 233(1): 83-6. [Abstract] [Full-text]
18. Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.
    J Neurol Sci, 233(1): 61-5. [Abstract] [Full-text]
19. The relation between MRI measures of inflammation and neurodegeneration in multiple sclerosis.
    J Neurol Sci, 233(1): 15-9. [Abstract] [Full-text]
20. Neuroprotective strategies in MS: lessons from C57BL/Wld(S) mice.
    J Neurol Sci, 233(1): 133-8. [Abstract] [Full-text]
21. Vitamin B12, demyelination, remyelination and repair in multiple sclerosis.
    J Neurol Sci, 233(1): 93-7. [Abstract] [Full-text]
22. Cortical lesions and brain atrophy in MS.
    J Neurol Sci, 233(1): 55-9. [Abstract] [Full-text]
23. Steroids and brain atrophy in multiple sclerosis.
    J Neurol Sci, 233(1): 73-81. [Abstract] [Full-text]
24. Steroid hormones in multiple sclerosis.
    J Neurol Sci, 233(1): 49-54. [Abstract] [Full-text]
25. Impact of sitting time on seat-interface pressure and on pressure mapping with multiple sclerosis patients.
    Arch Phys Med Rehabil, 86(6): 1221-5. [Abstract] [Full-text]
26. Movement preparation is affected by tissue damage in multiple sclerosis: evidence from EEG event-related desynchronization.
    Clin Neurophysiol, 116(7): 1515-9. [Abstract] [Full-text]
27. Evolving management of optic neuritis and multiple sclerosis.
    Am J Ophthalmol, 139(6): 1101-8. [Abstract] [Full-text]
28. The association of brainstem lesions with migraine-like headache: an imaging study of multiple sclerosis.
    Headache, 45(6): 670-7. [Abstract] [Full-text]
29. Initiation and exacerbation of autoimmune demyelination of the central nervous system via virus-induced molecular mimicry: implications for the pathogenesis of multiple sclerosis.
    J Virol, 79(13): 8581-90. [Abstract] [Full-text]
30. Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis.
    Arch Neurol, 62(6): 898-902. [Abstract] [Full-text]
31. Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy.
    Arch Neurol, 62(6): 889-94. [Abstract] [Full-text]
32. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement.
    Arch Neurol, 62(6): 865-70. [Abstract] [Full-text]
33. Mean diffusivity and fractional anisotropy histogram analysis of the cervical cord in MS patients.
    Neuroimage, 26(3): 822-8. [Abstract] [Full-text]
34. Mutations in the hemochromatosis gene (HFE) and multiple sclerosis.
    Neurosci Lett, 383(3): 301-4. [Abstract] [Full-text]
35. Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status.
    Intern Med J, 35(7): 382-7. [Abstract] [Full-text]
36. Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis.
    Eur J Neurol, 12(7): 550-6. [Abstract] [Full-text]
37. Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis.
    Eur J Neurol, 12(7): 514-8. [Abstract] [Full-text]
38. The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction.
    Neuroimage, 26(4): 1068-77. [Abstract] [Full-text]
39. Epidemiology of multiple sclerosis in Kuwait: new trends in incidence and prevalence.
    Eur Neurol, 53(3): 125-31. [Abstract] [Full-text]
40. Gluten sensitivity and neuromyelitis optica: two case reports.
    J Neurol Neurosurg Psychiatry, 76(7): 1028-30. [Abstract] [Full-text]
41. Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis.
    Lancet Neurol, 4(7): 403-12. [Abstract] [Full-text]
42. Genetic association between polymorphisms in the ADAMTS14 gene and multiple sclerosis.
    J Neuroimmunol, 164(1): 140-7. [Abstract] [Full-text]
43. The CTLA4 +49 A/G*G-CT60*G haplotype is associated with susceptibility to multiple sclerosis in Flanders.
    J Neuroimmunol, 164(1): 148-53. [Abstract] [Full-text]
44. Identifying nineteenth century genealogical links from genotypes.
    Hum Genet, 117(2): 188-99. [Abstract] [Full-text]
45. Optic radiation changes after optic neuritis detected by tractography-based group mapping.
    Hum Brain Mapp, 25(3): 308-16. [Abstract] [Full-text]
46. An investigation of NOS2A promoter polymorphisms in Australian multiple sclerosis patients.
    Eur J Hum Genet, 13(7): 815-22. [Abstract] [Full-text]
47. An examination of MS candidate genes identified as differentially regulated in multiple sclerosis plaque tissue, using absolute and comparative real-time Q-PCR analysis.
    Brain Res Brain Res Protoc, 15(2): 79-91. [Abstract] [Full-text]
48. Axon reactive B cells clonally expanded in the cerebrospinal fluid of patients with multiple sclerosis.
    J Clin Immunol, 25(3): 254-64. [Abstract] [Full-text]
49. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity.
    J Bone Miner Metab, 23(4): 309-13. [Abstract] [Full-text]
50. Inflammation and primary demyelination induced by the intraspinal injection of lipopolysaccharide.
    Brain, 128: 1649-66. [Abstract] [Full-text]
51. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis.
    Brain, 128: 1667-76. [Abstract] [Full-text]
52. Maternal - offspring HLA-DRB1 compatibility in multiple sclerosis.
    Tissue Antigens, 66(1): 44-7. [Abstract] [Full-text]
53. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging.
    Radiology, 236(1): 254-60. [Abstract] [Full-text]

© 2004-2008 Multiple Sclerosis Research Today. All Rights Reserved.